Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib

Tatsumichi, Takakiyo; Tanaka, Hiroaki; Okazaki, Tomoya; Takahashi, Koichi; Suzuki, Kenta; Kawakita, Kenya; Kuroda, Yasuhiro; Kosaka, Shinji

doi:10.1111/jcpt.13261

Cited by 4 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many drugs can cause PRES ( Abughanimeh et al, 2018 ; Vilas-Boas and Corte-Real, 2019 ; Kaur et al, 2020 ). With new antitumor agents widely used in the clinic in recent years, accumulating case reports have reported the occurrence of PRES in patients receiving targeted therapies, particularly antiangiogenic agents, such as bevacizumab ( Hamid et al, 2018 ; Katada et al, 2018 ), sunitinib ( Saraceno et al, 2017 ; Rifino et al, 2020 ), sorafenib ( Dogan et al, 2010 ; Laruelle et al, 2018 ), pazopanib ( Deguchi et al, 2018 ; Tatsumichi et al, 2021 ) and regorafenib ( Aanes et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review

Zou

Zhou²,

Lv³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Anlotinib is an oral multi-targeted tyrosine kinase inhibitor as a third-line and subsequent treatment for patients with small cell lung cancer (SCLC) in China. The neurotoxicity is less reported. Posterior reversible encephalopathy syndrome (PRES) is characterized by headaches, seizures, encephalopathy, and visual disturbances, as well as focal reversible vasogenic edema seen on neuroimages. Here, we presented a case of PRES in a small cell lung cancer (SCLC) patient associated with anlotinib. A 37-year-old female patient, who had a history of diabetes, with extensive-stage SCLC received anlotinib after third-line chemotherapy. Ten cycles of anlotinib later, the patient experienced visual disturbance and was diagnosed with PRES based on the typical demyelination of white matter obtained in the brain magnetic resonance. During anlotinib therapy, the patient did not develop anti-VEGF therapy-induced hypertension. Subsequently, the patient stopped anlotinib, but she did not recover from symptoms. We also summarized the characteristics of fifty-four cases of PRES caused by antiangiogenic drugs in the literature. Based on our experience and the literature review, the incidence of PRES induced by antiangiogenic drugs is low, and the symptom can resolve upon stopping the medications. However, some cases still have a poor prognosis and the underlying mechanism requires further investigation. In addition, early detection and treatment of PRES are essential for physicians.

show abstract

Section: Discussionmentioning

confidence: 99%

Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review

Zou

Zhou²,

Lv³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Pazopanib

2021

Reactions Weekly

View full text Add to dashboard Cite

Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma

et al. 2022

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome (PRES) is a rare but severe neurological syndrome that may stem from the use of some medications. Although its mechanism is not well-known, hypertension and endothelial dysfunction have been mentioned in previous literature as being related. Lenvatinib serves as a neoplastic agent that inhibits the tyrosine kinase of vascular endothelial growth factor receptors (VEGFR). VEGFR inhibitors result in endothelial dysfunction and consequent hypertension by nitric oxide pathway suppression and endothelin (ET)-1 stimulation. We hypothesized that VEGFR inhibitors would cause PRES. Herein, we report the case of a 40-year-old man with olfactory neuroblastoma who developed PRES while undergoing treatment with lenvatinib, 7 months after initiation. The symptoms included loss of consciousness and seizures. Fortunately, the symptoms and presence of PRES in imaging resolved, 7 days and 1 month, respectively, after cessation of lenvatinib.

show abstract

Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib

Cited by 4 publications

References 21 publications

Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review

Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review

Pazopanib

Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma

Contact Info

Product

Resources

About